Switching GLP-1 Telehealth Providers: How to Protect Continuity of Care
Changing online GLP-1 providers involves more than forwarding a prescription. Here is what to prepare, what to expect, and how to reduce gaps in your care.
Start My Assessment →Provider review required. Treatment, prescriptions, specific medications, and results are not guaranteed.
Can I switch GLP-1 telehealth providers?
Switching is often possible, but a new clinician must independently evaluate you before any treatment can begin. Records from a prior provider can be helpful, but a prescription does not automatically transfer. The medication, dose, coverage, and refills you received elsewhere are not guaranteed to continue, and each element requires separate review and authorization.
Information current as of August 16, 2026.
What Transfers—and What Must Be Reviewed Again?
Understanding what can be shared versus what requires a fresh clinical review helps set realistic expectations before you begin the process.
| Item | Can it be shared? | What must be rechecked |
|---|---|---|
| Medical records & labs | Yes (with valid request) | A new clinician must independently interpret results; records do not obligate prescribing. |
| Medication history | Yes | Tolerability, response, interruptions, and current regimen must be reviewed. |
| Prescription | No (not automatic) | A new prescription is required; the prior prescription does not transfer to a new prescriber. |
| Dose | Partial | The clinician must verify the exact product, formulation, concentration, and dose history before continuing, changing, or declining. |
| Membership / subscription | No | Memberships are provider-specific. Old memberships, refills, or shipments may require separate cancellation per prior provider terms. |
| Pharmacy relationship | No | A new prescription may be needed; pharmacy must be licensed in your state and authorized by the new prescriber. |
| Insurance coverage | No | Coverage depends on plan, formulary, network, prescriber, and pharmacy. Prior coverage does not guarantee future coverage. |
| Prior authorization | No | A new prior authorization may be required from the new prescriber and pharmacy. Prior approvals do not automatically transfer. |
Records do not obligate a new clinician to prescribe. Old memberships, refills, or pending shipments may require separate cancellation directly with your prior provider.
GLP-1 Transfer Checklist: What to Gather Before You Switch
Bringing complete, accurate information to your new provider assessment helps the reviewing clinician understand your history. Gather as much of the following as possible.
- Exact product and active ingredient: The full name of the medication you have been taking, including the active ingredient (e.g., semaglutide, tirzepatide).
- FDA-approved brand or compounded status: Whether your medication was an FDA-approved branded product or a compounded preparation, and the name of the compounding pharmacy if applicable.
- Route and formulation: How you take the medication (e.g., subcutaneous injection, oral tablet, oral dissolving tablet) and the specific formulation.
- Strength, concentration, and dosing details: The milligram strength, concentration (e.g., mg/mL for injectables), the volume or syringe units you were instructed to draw, your dosing schedule, and the date of your last dose.
- Full label photo: A clear photograph of the medication label, including lot number, expiration date, and all printed instructions.
- Prescriber and pharmacy information: The name and contact information of your prior prescriber and the pharmacy that dispensed your medication.
- Treatment timeline: Your start date, any titration steps taken, any interruptions or missed doses, side effects or adverse effects experienced, and your reason for switching providers.
- Medical and medication history: Current medical conditions, known allergies, pregnancy status or plans, all prescription medications, over-the-counter medications, and supplements; any recent urgent care or emergency visits; and relevant recent labs or clinical notes.
- Insurance and prior authorization documents: Any insurance cards, explanation-of-benefits documents, or prior authorization approval letters related to your GLP-1 treatment.
- Remaining supply and prior provider terms: How much medication you have remaining, when your current supply or subscription renews, and the cancellation terms of your prior provider.
How Can I Reduce the Chance of a Gap in Treatment?
No approach eliminates the possibility of a gap, but taking organized steps before your supply runs out can help minimize delays. HIPAA generally gives patients the right to access their own records and to request that records be sent to another provider; however, treatment sharing is permitted but not automatic, and timing and state-specific rules vary. Request records early.
Begin Before Your Supply Is Exhausted
Start the process while you still have medication remaining. Clinical review, follow-up questions, and pharmacy coordination all take time. No specific lead time can be promised, as timelines depend on your history, the clinician’s review, and external factors.
Request Records and Retain a Copy
Submit a records request to your prior provider as early as possible. Keep a personal copy of all records, lab results, and medication labels. HIPAA generally permits valid requests to have records sent to another provider, but timing and state rules vary.
Complete Your Assessment Honestly
Provide complete and accurate information during your new provider assessment, including your full medication history, current dose, any interruptions, and all other medications and supplements. Incomplete information can delay or affect the clinical review.
Wait for Instructions Before Acting
Do not adjust your dose, overlap medications, or restart after an interruption without explicit instructions from the clinician managing your care. While waiting, coordinate pharmacy, insurance, and cancellation of prior memberships or shipments per your prior provider’s terms.
Will the New Provider Continue My Current Medication or Dose?
Not necessarily. After reviewing your complete history, the clinician may continue, change, delay, or decline treatment. The decision depends on the exact product and formulation you were taking, your dose and any interruptions, your tolerability and response, your full medical history, any contraindications, and all other medications you are taking.
Different GLP-1 products and formulations—whether oral, injected, branded, or compounded—are not dose-equivalent. No conversion or titration chart applies universally across products. Never assume that a dose from one product translates to the same dose of another.
Safety Callout Do not double a dose, shorten the dosing interval, overlap GLP-1 medications, attempt to convert doses between products, or restart after an interruption without explicit instructions from the clinician managing your care.
Missed-dose and restart directions differ by product and formulation. Always refer to the official prescribing information for the specific product you are taking, and follow the instructions provided by your clinician. No personalized directions are provided here.
Official prescribing information: FDA label (218316) · FDA label (217806)
What If I Missed Doses During the Switch?
Contact the clinician managing your transition before restarting or catching up on missed doses. The appropriate plan depends on the specific product and formulation you are taking, how much time has passed since your last dose, the dose you were on, any effects you experienced, and your current health status.
No single rule applies to all GLP-1 products or formulations. Do not assume that instructions for one product apply to another, or that resuming your prior dose is always appropriate after an interruption. Your clinician will provide guidance specific to your situation.
For product-specific missed-dose guidance, refer to the official prescribing information linked in the section above and follow your clinician’s instructions.
Can Compounded GLP-1 Care Transfer?
Compounded GLP-1 medications present additional considerations that require careful review by a licensed clinician.
What You Should Know About Compounded GLP-1s
- Compounded drugs are not FDA-approved and are not reviewed by the FDA for safety, efficacy, or quality before marketing.
- Continuation of compounded GLP-1 treatment is not guaranteed; a new clinician must independently evaluate whether it is appropriate.
- The clinician must verify the compounding pharmacy, the active ingredient, the specific formulation, the concentration, the directions, and the label before any treatment decision.
- Concentration, units, and volume are not interchangeable across compounded preparations or between compounded and branded products.
FDA Concerns and Safety Considerations
- The FDA has raised concerns about compounded GLP-1 products, including dosing errors, fraudulent or misleading labels, the use of unapproved salt forms, and challenges with adverse-event reporting.
- Never describe a compounded GLP-1 as a generic, identical, equivalent, or “the same as” an FDA-approved branded product.
- Not all compounding is illegal; licensed compounding pharmacies operate under specific regulatory frameworks. However, not all compounded products meet the same standards.
- See: FDA’s Concerns About Unapproved GLP-1 Drugs
Pharmacy, Insurance, and State Access
Pharmacy
A new prescription may be required even if you are continuing the same medication. Verify that the pharmacy is licensed in your state, that it can fill the specific prescription, and that it is authorized by your new prescriber. Use the FDA BeSafeRx tool to locate state-licensed online pharmacies.
Insurance
Coverage varies by insurance plan, indication, formulary, network, prescriber, pharmacy, and prior authorization status. Prior coverage with one provider does not guarantee coverage with a new provider, prescriber, or pharmacy. Never assume that insurance benefits will transfer automatically.
Location and State Licensing
Telehealth clinicians must be licensed and authorized to practice in the state where you are physically located during the visit. If you have moved or are traveling, this may affect your access to care. See: HHS Telehealth Licensing Across State Lines
When Should I Seek Help Instead of Waiting for a Transfer?
Do not wait for a routine provider visit if you are experiencing severe or concerning symptoms.
Seek urgent or emergency care promptly for any of the following: signs of a possible severe allergic reaction; severe or persistent abdominal pain; repeated vomiting or signs of dehydration; or severe low blood sugar. Contact a clinician promptly—without waiting for a scheduled visit—if you become pregnant or experience a significant change in your health status. This content does not diagnose any condition. When in doubt, seek care.
How DietsMD Reviews a Possible GLP-1 Transfer
DietsMD uses a structured, clinician-led process for evaluating patients who are considering a provider transition. There is no instant transfer, automatic approval, guaranteed identical dose, guaranteed shipping timeline, or promise of uninterrupted care.
Complete a Secure Assessment
Begin with a secure online assessment. Provide complete and accurate information about your health history, current medications, and GLP-1 treatment history.
Provide Requested History and Medication Details
You may be asked to submit records, lab results, medication labels, or additional information. Respond promptly and completely to support the clinical review.
Licensed Provider Review and Follow-Up
A licensed provider reviews your submitted information and may ask follow-up questions. The provider independently determines whether treatment is appropriate and, if so, what medication, formulation, and dose are suitable for you.
Pharmacy Coordination and Ongoing Follow-Up
If treatment is prescribed, pharmacy coordination and follow-up care proceed under DietsMD’s current terms and conditions. Ongoing care is subject to continued clinical review and provider availability.
Provider review required. Treatment, prescriptions, specific medications, and results are not guaranteed.
Frequently Asked Questions
Can a new provider continue my GLP-1 prescription?
A new provider may continue your GLP-1 treatment, but this is not automatic. The clinician must independently review your medical history, the specific product and formulation you were taking, your dose and any interruptions, your tolerability and response, and any contraindications. The clinician may continue, modify, delay, or decline treatment based on that review.
Must I start over after switching?
Not necessarily, but the new clinician must conduct an independent evaluation. Depending on your history, the clinician may recommend continuing at your current dose, adjusting the dose, or beginning at a lower dose. The decision is based on your individual clinical picture, not a universal rule.
Can my former provider send records directly?
HIPAA generally gives patients the right to request that their records be sent to another provider. You can submit a valid records request to your prior provider asking them to transmit your records directly to a new provider. Timing, format, and any applicable fees vary by provider and state. Request early, as processing times differ.
How long does switching GLP-1 providers take?
No specific timeline can be promised. The process depends on how quickly you complete your assessment, how long records retrieval takes, the complexity of your clinical history, and any follow-up questions from the reviewing clinician. Starting the process before your current supply is exhausted can help reduce the chance of a gap.
Will my prior authorization transfer?
Prior authorizations are typically tied to a specific prescriber, pharmacy, and insurance plan. A prior authorization obtained through your former provider generally does not transfer automatically. A new prior authorization may need to be submitted by your new prescriber through your insurance plan.
Can I change pharmacies without changing medication?
Changing pharmacies may require a new prescription, depending on the medication, state law, and the prescriber’s requirements. Verify that the new pharmacy is licensed in your state and authorized by your prescriber before assuming a transfer is possible. Insurance coverage may also vary by pharmacy.
Can I move from compounded to an FDA-approved GLP-1?
Transitioning from a compounded GLP-1 to an FDA-approved branded product requires a new prescription and clinical review. The products are not dose-equivalent, and the clinician must evaluate the appropriate starting dose for the FDA-approved product based on your history. Do not assume that your compounded dose translates directly to a branded product dose.
Can I change medications while switching providers?
Any change in medication—including switching between GLP-1 products or formulations—requires a new clinical evaluation and prescription. Do not change, combine, or overlap GLP-1 medications without explicit instructions from the clinician managing your care.
What happens if I miss doses during the switch?
Contact the clinician managing your transition before restarting or catching up on missed doses. The appropriate plan depends on the specific product and formulation, how much time has passed, the dose you were on, and your current health. No universal rule applies across all GLP-1 products. Follow your clinician’s instructions and refer to the official prescribing information for your specific product.
Ready to Explore a Provider-Guided Transition?
DietsMD’s licensed providers review your history and determine whether GLP-1 treatment is appropriate for you. No automatic approvals, no guaranteed doses—just a thorough clinical review.
Start My Assessment →Provider review required. Treatment, prescriptions, specific medications, and results are not guaranteed.
Primary Sources
- HHS: HIPAA Right of Access — Patient Right to Access Health Records
- HHS HIPAA FAQ: Can an Individual Direct Records to Another Provider?
- HHS Telehealth: Licensing Across State Lines
- FDA Prescribing Information — NDA 218316 (GLP-1 Product Label)
- FDA Prescribing Information — NDA 217806 (GLP-1 Product Label)
- FDA Drug Alert: FDA’s Concerns About Unapproved GLP-1 Drugs Used for Weight Loss
- FDA BeSafeRx: Locate a State-Licensed Online Pharmacy
- HealthCare.gov: Prescription Medications and Marketplace Coverage
